Início › Câncer de Ovário › Massachusetts
Ensaios clínicos de Câncer de Ovário em Massachusetts
67 estudos para Câncer de Ovário estão buscando participantes em locais em Massachusetts.
Cidades em Massachusetts
Texto oficial do estudo (Inglês)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- e mais 1
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 19 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06586957A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0221 - Tufts Medical Center - PPDS, Boston
- Site 0104 - Dana Farber Cancer Institute, Boston
- Site 0307 - Lahey Hospital and Medical Center, Burlington
- e mais 1
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05128825Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- Dana Farber Cancer Institute, Boston
Recrutando
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05287451Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 25 de set. de 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 24 de set. de 2026 · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- UMass Memorial Medical Center - Belmont Street /ID# 278628, Worcester
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Massachusetts Chan Medical School, Worcester
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07109726Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
- Tufts Medical Center, Boston
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 16 de set. de 2026 · NCT07718854A Study of Isoquercetin in People With Ovarian Cancer
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07303894A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Massachusetts General Hospital, Boston
- Umass Memorial Medical Center, Inc., Worcester
RecrutandoFase 2
Idades de 18 a 99 · Mulheres · Atualizado em 15 de set. de 2026 · NCT07023627FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Tufts, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 14 de set. de 2026 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Massachusetts General Hospital, Boston
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 14 de set. de 2026 · NCT06787612A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT05123482DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
RecrutandoFase 1
Idades 18 e acima · Mulheres · Atualizado em 11 de set. de 2026 · NCT06964009Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT07755436Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1/2
12 Months – 30 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
RecrutandoFase 1/2
Idades de 18 a 130 · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT05797168A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07182149A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT06840886Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
RecrutandoFase 1/2
Idades de 18 a 130 · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT05417594A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Beth Israel Deaconess Medical Center, Boston
- Baystate Medical Center, Springfield
Recrutando
Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Baystate Medical Center, Springfield
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 2
Idades 8 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05503797A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
- Beth Israel Deaconess Medical Center, Boston
RecrutandoFase 1
Idades 18 e acima · Mulheres · Atualizado em 23 de jul. de 2026 · NCT03854110First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- e mais 3
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT04389632Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.